A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate tolerability of the combination therapy of JNS002
and bortezomib in Japanese bortezomib-naive patients with multiple myeloma who have ever
received at least 1 line of chemotherapy.